DEALS: Mitsubishi Chemical buys Tanabe for $4.3B


Mitsubishi Chemical buys Tanabe for $4.3B


DEALS

WHO

WITH

WHAT

SCOOP

Mitsubishi Chemical Holdings

Tanabe Seiyaku

$4.3 billion buyout

Mitsubishi Chemical Holdings is buying Tanabe Seiyaku for $4.3 billion in a deal that will double its drug sales.

Schering-Plough

Anacor Pharmaceuticals

$625M licensing deal

The deal is for Anacor's experimental fungal therapy.

Cytyc Corporation

Adeza Biomedical Corporation

$452 acquisition

Cytyc makes surgical and diagnostic products targeting women's health and cancer diagnostics, and Adeza manufactures and markets products for women's health.

GlaxoSmithKline

XenoPort

$350M deal

XenoPort is selling most of the worldwide rights to XP13512, a new version of the nerve drug gabapentin, to GlaxoSmithKline for $75 million up front and $275 million.

Otsuka

GW Pharmaceuticals

$273M deal

GW Pharmaceuticals and Japan's Otsuka signed a deal to develop and market GW's cannabis-based drug Sativex in the U.S.

AstraZeneca

Regeneron Pharmaceuticals

$120 licensing deal

AstraZeneca will use Regeneron Pharmaceuticals use its VelocImmune technology to discover therapeutic antibodies.

Pfizer

BioRexis Pharmaceutical

Buyout

 BioRexis uses protein engineering technology in its work developing new therapies for diabetes.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.